Long-term proton pump inhibitor use is associated with vascular calcification in chronic kidney disease: A cross-sectional study using propensity score analysis

Drug Safety

Volumn 36, Issue 8, 2013, Pages 635-642

  Fusaro, Maria ^a   Noale, Marianna ^a   Tripepi, Giovanni ^a   Giannini, Sandro ^b   D'Angelo, Angela ^b   Pica, Angelo ^c   Calò, Lorenzo A ^d   Miozzo, Davide ^b   Gallieni, Maurizio ^e  

^a CNR   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c SANTA CHIARA HOSPITAL   (Italy)

^d UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^e SAN CARLO BORROMEO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PROTON PUMP INHIBITOR; WARFARIN;

ADULT; AORTA; ARTERY CALCIFICATION; ARTICLE; BLOOD VESSEL CALCIFICATION; CHRONIC KIDNEY DISEASE; CLINICAL EVALUATION; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; FEMALE; HEMODIALYSIS PATIENT; HUMAN; ILIAC ARTERY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPENSITY SCORE; RENAL REPLACEMENT THERAPY;

AORTA; AORTOGRAPHY; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; ILIAC ARTERY; MALE; MIDDLE AGED; PROPENSITY SCORE; PROTON PUMP INHIBITORS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; TIME FACTORS; VASCULAR CALCIFICATION;

EID: 84881188147     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-013-0062-6     Document Type: Article

References (33)

1. Thomson AB, Sauve MD, Kassam N, Kamitakahara H. Safety of the long-term use of proton pump inhibitors. World J Gastroenterol. 2010;16(19):2323-30.
2. Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296(24):2947-53.
3. Targownik LE, Lix M, Metge CJ, Prior HJ, Leung S, Leslie WD. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ. 2008;179(4):319-26.
4. Cannata-Andia JB, Roman-Garcia P, Hruska K. The connections between vascular calcification and bone health. Nephrol Dial Transplant. 2011;26(11):3429-36.
5. Russo D, Corrao S, Battaglia Y, et al. Progression of coronary artery calcification and cardiac events in patients with chronic renal disease not receiving dialysis. Kidney Int. 2011;80(1):112-8.
6. Schulz E, Arfai K, Liu X, Sayre J, Gilsanz V. Aortic calcification and the risk of osteoporosis and fractures. J Clin Endocrinol Metab. 2004;89(9):4246-53.
7. Moe SM, O'Neill KD, Reslerova M, Fineberg N, Persohn S, Meyer CA. Natural history of vascular calcification in dialysis and transplant patients. Nephrol Dial Transplant. 2004;19(9):2387-93.
8. Rosenbaum PR, Rubin DB. Assessing sensitivity to an unobserved binary covariate in an observational study with binary outcome. J R Stat Soc. 1983;45(2):212-8.
9. Souberbielle JCP, Roth H, Fouque DP. Parathyroid hormone measurement in CKD. Kidney Int. 2010;77(2):93-100.
10. Witteman JC, Grobbee DE, Valkenburg HA, et al. J-shaped relation between change in diastolic blood pressure and progression of aortic atherosclerosis. Lancet. 1994;343(8896):504-7.
11. Adamina M, Guller U, Weber WP, Oertli D. Propensity scores and the surgeon. Br J Surg. 2006;93(4):389-94.
12. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17(19):2265-81.
13. KDIGO clinical practice guideline for the diagnosis. Evaluation, prevention and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. Kidney Int Suppl. 2009;76(Suppl. 113):S1-130.
14. Nakagami H, Osako MK, Morishita R. New concept of vascular calcification and metabolism. Curr Vasc Pharmacol. 2011;9(1):124-7.
15. Danziger J. Vitamin K-dependent proteins, warfarin and vascular calcification. Clin J Am Soc Nephrol. 2008;3(5):1504-10.
16. Beazley KE, Deasey S, Lima F, Nurminskaya MV. Transglutaminase 2-mediated activation of beta-catenin signalling has a critical role in warfarin-induced vascular calcification. Arterioscler Thromb Vasc Biol. 2012;32(1):123-30.
17. Inoue T, Ogawa T, Ishida H, Ando Y, Nitta K. Aortic arch calcification evaluated on chest X-ray is a strong independent predictor of cardiovascular events in chronic hemodialysis patients. Heart Vessels. 2011;27(2):135-42.
18. Noordzij M, Cranenburg EM, Engelsman LF, et al. Progression of aortic calcification is associated with disorders or mineral metabolism and mortality in chronic dialysis patients. Nephrol Dial Transplant. 2011;26(5):1662-9.
19. Fusaro M, Crepaldi G, Maggi S, et al. Bleeding, vertebral fractures and vascular calcifications in patients treated with warfarin: hope for lower risks with alternative therapies. Curr Vasc Pharmacol. 2011;9(6):763-9.
20. Schousboe JT, Taylor BC, Kiel DP, Ensrud KE, Wilson KE, McCloskey EV. Abdominal aortic calcification detected on lateral spine images from a bone densitometer predicts incident myocardial infarction or stroke in older women. J Bone Miner Res. 2008;23(3):409-16.
21. Bolland MJ, Wang TK, van Pelt NC, et al. Abdominal aortic calcification on vertebral morphometry images predicts incident myocardial infarction. J Bone Miner Res. 2010;25(3):505-12.
22. Charlot M, Grove EL, Hansen PR, et al. Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. BMJ. 2011;342:d2690.
23. Yu EW, Bauer SR, Bain PA, Bauer DC. Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. Am J Med. 2011;124(6):519-26.
24. Ngamruengphong S, Leontiadis GI, Radni S, Dentino A, Nugent K. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol. 2011;106(7):1209-18.
25. Targownik LE, Leslie WD. The relationship among proton pump inhibitors, bone disease and fracture. Expert Opin Drug Saf. 2011;10(6):901-12.
26. Kuipers MT, Thang HD, Arntzenius AB. Hypomagnesaemia due to use of proton pump inhibitors: a review. Neth J Med. 2009;67(5):169-72.
27. Hoorn EJ, van der Hoek J, de Man RA, Kuipers EJ, Bolwerk C, Zietse R. A case series of proton pump inhibitor-induced hypomagnesemia. Am J Kidney Dis. 2010;56(1):112-6.
28. Regolisti G, Cabassi A, Parenti E, Maggiore U, Fiaccadori E. Severe hypomagnesemia during long-term treatment with a proton pump inhibitor. Am J Kidney Dis. 2010;56(1):168-1274.
29. Kanazawa I, Yamamoto M, Yamaguchi T, Yamauchi M, Yano S, Sugimoto T. A case of magnesium deficiency associated with insufficient parathyroid hormone action and severe osteoporosis. Endocr J. 2007;54(6):935-40.
30. Ishimura E, Lokuno S, Kitatani K, Tsuchida T, Yamakawa T, Shioi A, Inaba M, Nishizawa Y. Significant association between the presence of peripheral vascular calcification and lower serum magnesium in hemodialysis patients. Clin Nephrol. 2007;68(4):222-7.
31. Meema HE, Oreopooulos DG, Rapoport A. Serum magnesium level and arterial calcification in end-stage renal disease. Kidney Int. 1987;32(3):388-94.
32. Montezano AC, Zimmerman D, Yusuf H, et al. Vascular smooth muscle cell differentiation to an osteogenic phenotype involves TRPM7 modulation by magnesium. Hypertension. 2010;56(3):453-62.
33. Strid H, Fjell A, Simrén M, Björnsson ES. Impact of dialysis on gastroesophageal reflux, dyspepsia, and proton pump inhibitor treatment in patients with chronic renal failure. Eur J Gastroenterol Hepatol. 2009;21(2):137-42.